Presentation is loading. Please wait.

Presentation is loading. Please wait.

Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different.

Published byJeffery Oliver Modified over 5 years ago

Similar presentations

Presentation on theme: "Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different."— Presentation transcript:

1 Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different time points after initiation of anti-TB treatment. Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different time points after initiation of anti-TB treatment. Optical density (OD) results for HIV-positive participants are shown in red solid lines, results for HIV-negative participants as black dashed lines. The signal intensity became undetectable after 3 months of treatment in six participants. y-axis shows logarithmic scale for mean OD. Neg.: negative. Reproduced from [73]. Margarida Correia-Neves et al. ERJ Open Res 2019;5: ©2019 by European Respiratory Society

Download ppt "Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different."

Similar presentations

A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.

A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.
The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.
Echocardiography view

Echocardiography view
Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Dried blood spot for therapeutic drug monitoring. a).

Dried blood spot for therapeutic drug monitoring. a).
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
A) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. a) Biological onset (inception), pre-clinical and.

A) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. a) Biological onset (inception), pre-clinical and.
Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.

Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.

Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.
Survival without tracheostomy

Survival without tracheostomy
Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.
The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.

The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.
Mesenchymal stromal cell (MSC) phenotype from chronic obstructive pulmonary disease (COPD) and non-COPD patients. Mesenchymal stromal cell (MSC) phenotype.

Mesenchymal stromal cell (MSC) phenotype from chronic obstructive pulmonary disease (COPD) and non-COPD patients. Mesenchymal stromal cell (MSC) phenotype.
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Paediatric tuberculosis (TB) in Alberta by method of detection and strategically placed TB elimination activities. Paediatric tuberculosis (TB) in Alberta.

Paediatric tuberculosis (TB) in Alberta by method of detection and strategically placed TB elimination activities. Paediatric tuberculosis (TB) in Alberta.
Bland–Altman plot of slopes of measurement 1 versus 2

Bland–Altman plot of slopes of measurement 1 versus 2

Similar presentations

Ads by Google